Cornerstone Therapeutics Completes Acquisition of EKR Therapeutics

Cornerstone Therapeutics Inc. announced the closing of its acquisition of EKR Therapeutics, Inc., a privately-held specialty pharmaceutical company focused on the acute-care hospital setting. Pursuant to the merger agreement, EKR Therapeutics became a wholly owned subsidiary of Cornerstone. The merger was effective June 26, 2012.

If you have any questions about the merger, please contact Josh Franklin at (919) 678-6520.